Transaction in Own Shares

• Press Release
• Source: Novo Nordisk A/S
• On 8:35 am EST, Monday December 1, 2008

BAGSVAERD, DENMARK--(MARKET WIRE)--Dec 1, 2008 -- Novo Nordisk A/S - Share repurchase programme

Related Quotes

Symbol	Price	Change
NONOF.PK	62.40	0.00

{"s" : "nonof.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}

On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008.

Since the announcement as of 24 November 2008, the following transactions have been made under the programme:

 
                  Number of    Average      Transaction
                   shares   purchase price  value, DKK
Accumulated, last
announcement      3,951,500                1,124,730,754
24 November 2008     50,000    267.4700       13,373,500
25 November 2008    105,000    268.8400       28,228,200
26 November 2008     70,000    268.5300       18,797,100
27 November 2008     70,000    274.9700       19,247,900
28 November 2008     80,000    291.1100       23,288,800
Accumulated under
the programme     4,326,500                1,227,666,254

With the transactions stated above, Novo Nordisk owns a total of 25,293,285 treasury shares, corresponding to 4.0% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

 
Further information:

Media:                 Investors:

Outside North America  Mads Veggerby Lausten
Elin K Hansen          Tel: (+45) 4443 7919
Tel: (+45) 4442 3450   mlau@novonordisk.com
ekh@novonordisk.com
                       Hans Rommer
In North America:      Tel: (+45) 4442 4765
Sean Clements          hrmm@novonordisk.com
Tel: (+1) 609 514 8316
secl@novonordisk.com   Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       krop@novonordisk.com

Company Announcement no 78 / 2008

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.